Saracatinib在肺纤维化临床前模型中阻断纤维化反应
本研究基于计算机模拟数据驱动方法,发现IPF转录组扰动与Src激酶抑制剂saracatinib诱导的转录组变化高度相关。在体外、体内和离体三种临床前模型中,saracatinib阻断纤维化反应的效果等于或优于尼达尼布和吡非尼酮。转录组分析显示saracatinib独特地改变了EMT、TGF-β和WNT信号通路,并逆转了多种促纤维化通路。
要点
- Saracatinib在三种肺纤维化临床前模型中抗纤维化效果等于或优于尼达尼布和吡非尼酮
- Saracatinib独特改变TGF-β刺激的成纤维细胞中EMT、TGF-β和WNT信号相关基因集
- Saracatinib逆转动物模型全肺提取物中EMT、免疫反应和细胞外基质组织等纤维化通路
核心结论
- 这些研究识别了新的Src依赖性促纤维化通路,支持研究saracatinib治疗IPF的疗效。
研究设计与样本
- 研究在三种临床前模型中评估saracatinib相对于尼达尼布和吡非尼酮的抗纤维化疗效:体外正常人类肺成纤维细胞、体内博来霉素和重组Ad-TGF-β小鼠肺纤维化模型、离体小鼠和人类精确切割肺切片。
主要发现
- 在每个模型中,saracatinib阻断纤维化反应的效果等于或优于尼达尼布和吡非尼酮。
- 对TGF-β刺激的正常人类肺成纤维细胞进行转录组分析,识别出与纤维化相关的特定基因集,包括上皮-间质转化、TGF-β和WNT信号,这些被saracatinib独特地改变。
- 对两种动物模型全肺提取物的转录组分析显示,saracatinib逆转了许多促纤维化通路,包括上皮-间质转化、免疫反应和细胞外基质组织。
- 人类精确切割肺切片中纤维化和炎症级联的改善证实了saracatinib在人类肺纤维化中的潜在治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal disorder. Two U.S. Food and Drug Administration-approved antifibrotic drugs, nintedanib and pirfenidone, slow the rate of decline in lung function, but responses are variable and side effects are common. Objectives: Using an in silico data-driven approach, we identified a robust connection between the transcriptomic perturbations in IPF disease and those induced by saracatinib, a selective Src kinase inhibitor originally developed for oncological indications. Based on these observations, we hypothesized that saracatinib would be effective at attenuating pulmonary fibrosis. Methods: We investigated the antifibrotic efficacy of saracatinib relative to nintedanib and pirfenidone in three preclinical models: 1) in vitro in normal human lung fibroblasts; 2) in vivo in bleomycin and recombinant Ad-TGF-β (adenovirus transforming growth factor-β) murine models of pulmonary fibrosis; and 3) ex vivo in mice and human precision-cut lung slices from these two murine models as well as patients with IPF and healthy donors. Measurements and Main Results: In each model, the effectiveness of saracatinib in blocking fibrogenic responses was equal or superior to nintedanib and pirfenidone. Transcriptomic analyses of TGF-β-stimulated normal human lung fibroblasts identified specific gene sets associated with fibrosis, including epithelial-mesenchymal transition, TGF-β, and WNT signaling that was uniquely altered by saracatinib. Transcriptomic analysis of whole-lung extracts from the two animal models of pulmonary fibrosis revealed that saracatinib reverted many fibrogenic pathways, including epithelial-mesenchymal transition, immune responses, and extracellular matrix organization. Amelioration of fibrosis and inflammatory cascades in human precision-cut lung slices confirmed the potential therapeutic efficacy of saracatinib in human lung fibrosis. Conclusions: These studies identify novel Src-dependent fibrogenic pathways and support the study of the therapeutic effectiveness of saracatinib in IPF treatment.
引用
- Ahangari F, Becker C, Foster DG, et al. Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022. PMID: 35998281. doi:10.1164/rccm.202010-3832OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。